News

How are Dr Moffic’s social psychiatric resolutions doing? Let’s check in.

Yale School of Medicine and VA Connecticut Healthcare System researchers compared social determinants of health in relation to the risk of suicide, a major global public health issue and one of the leading causes of death in the United States.

Check out the pipeline updates from January!

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

Meditation using immersive virtual reality devices can help alleviate symptoms of major depressive disorder and generalized anxiety disorder.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

How does one clinician use art to process emotions, foster resilience, bridge the space between self-states?

Psychiatry may often encounter suicide and homicide, but what is its relationship with ecocide and genocide?

Patients are now being recruited for a study to compare the effectiveness of IV ketamine and esketamine nasal spray (otherwise known as Spravato) for people who suffer from treatment-resistant depression.

How are organizations in Montana working to help better mental health care accessible across the state?

The clock is ticking…

Showcasing cutting edge research and exploring best practices in ADHD diagnosis and treatment.

Artists may struggle with feelings of uselessness in dark times, but here’s why their work is more important than ever.

According to a new study, the launch of 988 did not equate to significant, equitable growth in availability of crisis services.

New positive results of a pharmacokinetics study of AD04 for alcohol use disorder confirms the near micro-dosing regimen planned for upcoming trials.

How should clinicians approach loneliness in elderly patients, and how can technology assist in treatment?

From dealing with grief to treating a condition, healing can't come with just a magic pill.

Check out new positive topline results from the open-label phase 2A study of BPL-003 in participants with moderate-to-severe alcohol use disorder.

How does affluence impact mental health outcomes?

Neurocrine is initiating a phase 3 study of osavampator for the treatment of adults with major depressive disorder.

Let’s set the clock on Doomsday.

According to a new label update, the transfer of Qelbree into breastmilk is low.

Today is International Holocaust Remembrance Day.

Struggling with complex psychiatric diagnoses? Consider the diagnostic prism.

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

In this CME article, learn more about alternative methods to screen for lithium-related polyuria and how to implement amiloride for lithium-related polyuria.

When wicked problems arise, can we defy gravity?

Check out some of the top clinical pearls gleaned from presenters at Real Psychiatry.

Here's how best to manage polypharmacy in patients with traumatic brain injury.